ROG

Rogers Corporation (ROG) Q2 2026 Earnings Call Transcript

Rogers NYSE: ROG reported second-quarter 2026 sales growth and substantially higher profitability, while outlining a third-quarter outlook that calls for revenue growth across each of its major end markets.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the second quarter of 2026. "We delivered another quarter of solid revenue growth, with sales increasing nearly 7% year over year, driven by improving customer demand and progress in our commercial initiatives,” stated Ali El-Haj, Rogers' President and CEO. "Compared to the prior year adjusted EPS improved significantly and EBITDA margin expanded by 550 basis points, despite supply chain challe.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE: ROG) today released its 2026 Sustainability Report, outlining Rogers' approach to managing environmental impacts, supporting employees, maintaining strong governance practices, and developing advanced materials that help customers improve efficiency and enable next-generation technologies. “We are pleased to share our 2026 Sustainability Report,” said Ali El-Haj, Rogers President and Chief Executive Officer. “The report reflects our on.

CHANDLER, Ariz.--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce second quarter 2026 results on July 28, 2026 after market close, which will be followed by a conference call at 5:00 pm ET. The call will be hosted by Ali El-Haj, President and Chief Executive Officer, who will be joined by Laura Russell, Senior Vice President and Chief Financial Officer. A live webcast of the event and related slide presentation can be accessed on Rogers' Investor Relations website at.

ASYS, ROG and CMI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 25th, 2026.

JLL, ADM, CMI, ROG and ASYS have been added to the Zacks Rank #1 (Strong Buy) List on June 25th, 2026.

Rogers Corp. (ROG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zealand Pharma said on Friday its experimental obesity drug, co-developed with Swiss partner Roche , showed encouraging tolerability in a mid-stage trial, bolstering ​its push to take on market leaders with a potentially ‌gentler alternative to existing blockbuster treatments.

After losing some value lately, a hammer chart pattern has been formed for Rogers Corp. (ROG), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.